Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
NEW YORK, May 15, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of TherapeuticsMD, Inc. (NYSEMKT:TXMD) who purchased shares between July 7, 2016 and April 9, 2017. The action, which was filed in the USDC for the Southern District of Florida, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-004HR NDA.
Shareholders have until June 19, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/therapeuticsmd-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
